← Evidence library

BIB_376

KEYNOTE-054 / EORTC1325 7-year analysis — adjuvant pembrolizumab vs placebo in resected Stage III melanoma: RFS HR 0.63 (50% vs 36% at 7yr); DMFS HR 0.64 (54% vs 42%); PRFS2 HR 0.69 (61% vs 53%); benefit consistent across IIIA/B/C, PD-L1+/−, and BRAF mut/WT. OS data planned after 380 deaths (not yet mature; expected ~2026-2027). Most mature adjuvant Stage III RCT data available; fills the "OS still pending" gap in TASK17 and confirms KEYNOTE-054 benefit is durable through year 7.

Evidence grade

A

Tier

1 (Phase 3 double-blind RCT, N=1,019, 123 sites, 23 countries; 7-year pre-specif

Cited by tasks

17, 18, 19b

Identifiers

DOI:10.1016/j · PMID:29658430

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_376/findings.md (research corpus). This page is a short context summary — not individualised medical advice.